. 2017 Apr 3;59:e2. doi: 10.1590/S1678-9946201759002

Table 2. Seroprevalence and log-transformed geometric mean titers of Yellow Fever (YF) neutralizing antibody (Ab) measured by Plaque Reduction Neutralization Test (PRNT₅₀) among participants aged 60 years or more (Group 1) and under-60 years (Group 2).

	Group 1 (≥ 60 y) n=46 n^o (%)	Group 2 (18 - 59 y) n=48 n^o (%)	p-value
Seroprevalence (neutralizing Ab, mIU/mL)^#
Positive Negative	40 (87.0) 6 (13.0)	45 (93.8) 3 (6.3)	0.263
YF neutralizing Ab titer (log10mIU/mL) (n=88)*
Mean (SD, CI 95%) Median (min - max)	3.44 (0.43, 3.35-3.53) 3.48 (2.38 - 4.28)	3.64 (0.36, 3.56-3.71) 3.67 (2.77 - 4.27)	0.022

# Cutoff=794mIU/mL, equivalent of 2.9 log₁₀mIU/mL.

*Participants without exact titer were excluded from this analysis (four with results above the upper limit of the test and two below the lower limit of the test).

Table 2. Seroprevalence and log-transformed geometric mean titers of Yellow Fever (YF) neutralizing antibody (Ab) measured by Plaque Reduction Neutralization Test (PRNT50) among participants aged 60 years or more (Group 1) and under-60 years (Group 2).

Table 2. Seroprevalence and log-transformed geometric mean titers of Yellow Fever (YF) neutralizing antibody (Ab) measured by Plaque Reduction Neutralization Test (PRNT₅₀) among participants aged 60 years or more (Group 1) and under-60 years (Group 2).